1. United States of America Stocks

  2. •

    Basic Materials

  3. •

    Agricultural Inputs
Igene Biotechnology, Inc.

Igene Biotechnology, Inc.

IGNE
Igene Biotechnology, Inc.US flagOther OTC
0.00
USD
- -
- -
15,654.00Market Cap
1999 Y
2000 Y
2001 Y
2002 Y
2003 Y
2006 Y
2007 Y
2008 Y
2009 Y
TTM
Revenue per Share
- -
0.01
0.06
0.04
0.01
- -
0.02
0.04
- -
- -
Basic EPS, GAAP
-0.07
-0.04
-0.05
-0.04
-0.02
-0.01
-0.02
-0.02
- -
- -
Free Cash Flow per Basic Share
-0.05
-0.03
-0.03
-0.02
- -
- -
0.01
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.81
-0.53
-0.44
-0.44
-0.42
-0.39
-0.43
-0.2
-0.02
-0.03
Tangible Book Value per Share
-0.21
-0.15
-0.14
-0.17
-0.04
-0.15
-0.13
-0.02
- -
- -
Basic Weighted Avg Shares
34
56
76
82
90
108
110
187
1,538
1,565
Sales/Revenue/Turnover
- -
1
4
3
- -
- -
2
8
4
- -
Operating Margin (%)
-7,215.64
-214.89
-39.18
-53.01
-134.79
- -
2.94
-28.63
0.62
-12,422.29
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-3
-2
-4
-3
-2
-1
-2
-4
- -
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-13,928.3
-321.03
-87.85
-91.36
-474.48
- -
-83.05
-52.21
-3.56
-49,414.7
Working Capital
1
1
- -
- -
1
-1
4
2
2
- -
LT Debt
8
8
10
11
11
15
13
6
6
6
Total Equity
-7
-8
-11
-14
-4
-16
-14
-3
-3
-5
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'10
Jun'10
Sep'10
ST Debt
1
2
2
LT Borrowings
6
6
6
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,565
1,565
1,565
Market Capitalization
17
8
16

Working Capital

FRC

•

in mil. unless spec.
Mar'10
Jun'10
Sep'10
Total Current Assets
4
3
2
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
- -
- -
1
ST Debt
1
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
31.14%
2.42%
Free Cash Flow
- -
206,977.49%
-156.07%
Net Income, GAAP
- -
-0.1%
-96.47%
Sales/Revenue/Turnover
- -
- -
-48.23%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
3
2
2
1
8
2009
1
2
1
- -
4
2010
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
-0.01
-0.01
-0.01
- -
-0.02
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Joseph L. Downs
Full Time Employees
18
Sector
Basic Materials
Industry
Agricultural Inputs
Address
9110 Red Branch Road Columbia MD United States of America 21045
IPO Date
Feb 2, 1995
CIK
0000793160
Website
igene.com
Similar Companies
Madras Fertilizers Limited (MADRASFERT.NS)
Shivalik Rasayan Limited (SHIVALIK.BO)
Mahaan Foods Limited (MAHAANF.BO)
Rallis India Limited (RALLIS.BO)
Anhui Sierte Fertilizer industry Ltd. ,company (002538.SZ)
India Pesticides Limited (IPL.NS)
Business
Igene Biotechnology, Inc. Igene Biotechnology, Inc. (IGNE) engages in the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. The company supplies natural astaxanthin, marketed as AstaXin and produced from yeast, serving as a nutrient and pigment source for coloring farmed salmon and trout species; it also provides ingredients and finished products to the nutraceutical and animal feed industries, alongside research and development services encompassing microbial strain improvement, fermentation process development and scale-up from shake flasks to commercial fermentors, and analytical chemistry services for carotenoid identification and quantification in foods, feeds, and animal tissues, including verification of wild versus farmed salmonids. Founded in 1981 and headquartered at 9110 Red Branch Road, Suite J, Columbia, Maryland, the company operates primarily in the United States with worldwide marketing of its fermentation technology, nutrition, and health applications. Formerly known as IGI Biotechnology, Inc., it changed its name to Igene Biotechnology, Inc. in April 1986. In recent developments, the company has secured strategic partnerships and funding to support R&D initiatives, enhancing its product pipeline and market position in the biopharmaceutical and agricultural inputs sectors.